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Low molecular weight gelators (LMWGs) of chemotherapeutic drugs represent a valid alternative to the existing polymer-
based formulations used for targeted delivery of anticancer drugs. Herein we report the design and development of novel 
self-assembling  gelators of the antitumour benzothiazole 5F 203 (1). Two different types of derivatives of 1 were synthesized, 
formed by an amide (2) and a carbamate (3a-3d) linker, respectively, which showed potent in vitro antitumour activity 
against MCF-7 mammary and IGROV-1 ovarian carcinoma cells. In contrast, MRC-5 fibroblasts were inherently resistant to 
the above derivatives (GI50>10 μM), thus revealing stark selectivity against the malignant cell lines over the non-transformed 
fibroblasts. Western blots assays demonstrated induction of CYP1A1 by 1 and its derivatives only in sensitive malignant cells 
(MCF-7), corroborating conservation of CYP1A1-mediated mechanism of action. The ability to form stable gels under rela-
tively high strains was supported by rheological tests; in addition, their inner morphology was characterized as possessing 
a crossed-linked nanostructure, with formation of thick aggregates with variable widths between 1100 nm and 400 nm and 
lengths from 8 μm to 32 μm. Finally, in vitro dissolution studies proved the ability of hydrogel 2 to release 48% of 2 within 
80 hours, therefore demonstrating its ability to act as a platform for localized delivery.
1. INTRODUCTION 
Low molecular weight gelators (LMWGs) have recently be-
come an attractive group of soft biomaterials with excep-
tional tunable properties that make them suitable for drug 
delivery applications.1-3 They have been reported to be via-
ble alternatives to the extensively explored polymer-based 
drug delivery systems, due to their biocompatibility, bio-
degradability and ability to control drug release. One of the 
most successful applications of LMWGs involves the de-
sign of self-assembling derivatives as stimuli-responsive bi-
omaterials.4 This approach consists of covalently conjugat-
ing functional moieties, such as peptides, amino acids or 
fatty acids, to active drugs, in order to create amphiphilic 
derivatives which self-assemble in different solvents 
(mainly water) to form a gel depot, from which the active 
agent is released after hydrolysis or enzymatic degrada-
tion.5 To date, examples of antibacterial, anti-inflamma-
tory and chemotherapeutic LMWGs developed with this 
strategy have been reported. 3, 6, 7 In particular, LMWGs of 
chemotherapeutic drugs represent a valid alternative to 
the existing polymer-based formulations used for targeted 
delivery of anticancer drugs, because of their higher drug 
loading, lack of excipients, and consequent increased in 
situ drug concentrations.3 To date, most of the examples in 
the literature of chemotherapeutic LMWGs are those re-
ported by Xu and Yang, based on the anticancer drug 
paclitaxel. They exploited short peptides and folic acid as 
functional moieties to create several examples of Taxol® 
hydrogels for targeted cancer therapy.8-10 A recent compre-
hensive review by Xu and his collegues summarized the 
methods used to generate supramolecular hydrogels and 
their applications as molecular biomaterials.11 Our group 
recently reported another example of a chemotherapeutic-
based LMWG. We synthesized amino acid deriavtives of 
the experimental anticancer agent 2‐(4‐amino‐3‐
methylphenyl)‐5‐fluorobenzothiazole (5F 203, 1), which 
formed metastable gels in mixtures of organic solvents 
(DMSO) and water. Amino acid derivatives of 1 also dis-
played in vitro activity against ovarian and breast cancer 
cell lines.12 1 was initially selected for these studies as it had 
been previously identified as the lead compound of a fam-
ily of benzothiazole derivatives with exquisitely potent and 
highly selective antitumour activity in certain tumour 
models including breast and ovarian cancer cell lines.13, 14 
Its mechanism of action is distinct from chemotherapeutic 
agents in the clinical arena. After binding to the cytosolic 
arylhydrocarbon receptor (AhR), the complex of 1 and AhR 
translocate to the nucleus; dimerise with AhR nuclear 
transportor and bind to the xenobiotic response element 
in the promotor region of genes in the AhR battery includ-
ing cyp1a115,16 Induction of cyp1a1 transcription and protein 
expression results in CYP1A1-catalysed bioactivation of 1 to 
electrophilic reactive species, 13, 17 which generate DNA ad-
ducts leading to lethal DNA strand breaks and cell death.18  
The lysylamide derivative of 1, Phortress, developed to 
overcome 1 high lipophilicity and poor aqueous solubility,19 
was progressed to clinical trials.20 Including our recent gel 
 studies, very few examples of self-assembling benzothia-
zole derivatives have been reported in the literature, which 
refer to formation of organogels from binary mixtures.21, 22 
Herein, we have further developed novel self-assembling  
gelators based on 1. In particular, we have identified two 
different types of derivatives of 1 formed by an amide (2) 
and a carbamate (3) linker, respectively (Fig. 1). We also 
show how structural differences led to different in vitro and 
gelation properties. Finally, we selected a lead derivative of 
1 for further studies, demonstrating the potential ap-
plications of this gelator in drug delivery. 
2. EXPERIMENTAL SECTION 
Materials. Chemicals, solvents and buffers were pur-
chased from commercial suppliers and were used without 
further purification. Cell culture medium, supplements 
and foetal bovine serum were purchased from Sigma Al-
drich. Human plasma was purchased from TCS Biosci-
ences. 
General methods. Reactions were monitored by thin 
layer chromatography (TLC) on commercially available 
precoated aluminium-backed plates (Merck Kieselgel 60 
F254).Visualisation was carried out by examination under 
UV light (254 nm) or by staining with potassium perman-
ganate (KMnO4) solution. Organic solvents were evapo-
rated under reduced pressure at temperatures between 35 
°C and 45 °C (water bath). Purification by silica gel flash 
column chromatography was performed using silica gel 
Sigma Aldrich (technical grade, 40-63 μm particle size). 
Analytical Methodology. 1H NMR spectra were recorded 
on a Bruker 400 Ultrashield at 400 MHz at 25 °C. 13C NMR 
spectra were recorded on a Bruker 400 Ultrashield at 100 
MHz at 25 °C. Chemical shifts (δ) are reported in parts per 
million (ppm). DMSO-d6 was used as solvent for NMR 
analyses ((CHD2)2SO at δH 2.50 ppm, (CD3)2SO at δC 39.52 
ppm). The significant multiplicities are described by sin-
glet (s), doublet (d), triplet (t), doublet of a doublet (dd), 
triplet of a doublet (td) and multiplet (m). Coupling con-
stants (J) are recorded in Hz. Spectra were analyzed with 
Bruker TopSpin 3.0. High-resolution mass spectra 
(HRMS)-time of flight electrospray (TOF ES±) were rec-
orded using Waters 2795 spectrometer. Melting points 
were measured on Gallenkamp Melting Point Apparatus. 
Reverse phase high performance liquid chromatography 
(RP-HPLC) was performed using a Waters 2767 sample 
manager, Waters 2525 binary gradient module and visual-
ized at 254 nm with a Waters 2487 dual wavelength absorb-
ance detector. Spectra were analyzed using MassLynx. Pre-
parative RP-HPLC was performed using a Phenomenex 
Luna 10 µm C8 (2) 100 Å column (150 mm x 30 mm) at a 
flow rate of 20 mL/min using a preparative RP-HPLC 
method of 0-16 min gradient of 40% to 80% solvent B in 
solvent A, 16-18 min held at 80% solvent B in solvent A, 18-
20 min 80% to 40% solvent B in solvent A, 20-22 min held 
at 40% solvent B in solvent A. Analytical RP-HPLC was per-
formed using a Phenomenex Luna 5 µm C8 (2) 100 Å col-
umn (150 mm x 4.60 mm) at a flow rate of 1 mL/min. The 
retention time (tR) of products is reported using an analyt-
ical RP-HPLC method of 0-24 min gradient of 5% to 95% 
solvent B in solvent A, 24-26 min held at 95% solvent B in 
solvent A, 26-27 min 95% to 5% solvent B in solvent A, 27-
30 min held at 5% solvent B in solvent A (solvent A= 0.05 
% TFA in H2O, solvent B= 0.05 % TFA in 9:1 v:v 
CH3CN:H2O).  
HPLC analyses of benzothiazole derivative stability tests: 
To 100 μL sample, 10 μL internal standard solution (100 μM 
diclofenac in acetonitrile-water (1:1, v/v)) was added. Pro-
tein precipitation was accomplished by addition of 300 μL 
acetonitrile. A pH modifier of 300 μL 0.1 M HCl and 2 mL 
extraction solvent metyl-tert-butyl ether were added for 
liquid-liquid extraction. A vortex-mix of 10 min was applied 
and the samples were centrifuged at 1160 g for 10 min at 10 
°C. The organic layer was transferred and evaporated to 
dryness under N2 gas at 40 °C. The samples were reconsti-
tuted with 100 μL acetonitrile-water (1:1, v/v) and vortex-
mixed for 1 min prior to HPLC analysis. The HPLC-UV sys-
tem consisted of a Waters 600 Pump, Waters 717 Au-
tosampler and Waters 2996 Photodiode Array Detector. 
Chromatographic separation was accomplished by Gemini 
C18 2.0 x 150 mm, 3 μm particle size column equipped with 
a SecurityGuard 2 × 4 mm, 3 μm particle size (Phenomenex, 
Macclesfield, UK). A mixture of acetonitrile-water was 
used for mobile phase in ratios of 60:40 (v/v) at a flow rate 
of 0.35 mL/min. Chromatograms were observed at 347, 325 
and 278 nm for 1, the derivatives of 1 and diclofenac, re-
spectively. 
Synthesis of compound 2. 2‐(4‐Amino‐3‐methylphenyl)‐
5‐fluorobenzothiazole (5F 203, 1; 1.94 mmol, 0.50 g) and 
succinic anhydride (46.56 mmol, 4.65 g) were suspended 
in dry pyridine (30 mL) and the reaction mixture was 
stirred at 60 °C to effect full dissolution and the solution 
was then maintained at this temperature for a further 15 h. 
Figure 1: Molecular structures of 1, the succinic amide derivative (2) 
and the carbamate-based derivatives (R=CH3, CH2CH3, CH(CH3)2, 
C(CH3)3) (3a-3d). 
 The cooled solution was evaporated under reduced pres-
sure  to afford a semi-solid material which was then tritu-
rated with water to aid removal of residual pyridine. The 
solid was then collected via vacuum filtration and purified 
using preparative RP-HPLC (0.29 g, 42% yield). 1H NMR 
(400 MHz, DMSO-d6): δ 12.15 (s, 1H, COOH), 9.45 (s, 1H, 
NH),  8.17 (dd, 1H, J= 5.4, 8.8 Hz, H-7), 7.94 (d, J= 1.7 Hz, 
1H, H-4), 7.89-7.85 (m, 2H, H-2’, H-6’), 7.76 (d, J= 8.7 Hz, 
1H, H-5’), 7.36 (td, J= 2.5, 8.9 Hz, 1H, H-6), 2.66 (t, J= 6.5 
Hz, 1H, CH2-COOH), 2.55 (t, J= 6.3 Hz, 1H, CH2), 2.34 (s, 
3H, CH3). 13C NMR (100 MHz, DMSO-d6): 173.79, 170.49, 
169.79, 162.58, 160.19, 154.54, 139.80, 130.16, 128.98, 125.15, 
123.63, 113.77, 113.52, 108.70, 108.47, 30.78, 29.04, 17.82. Mp: 
222-224 °C. MS: m/z (HRMS) calculated for C18H16FN2O3S+ 
359.0860 [M+H], MS found: 359.0938 [MH]+. Analytical 
RP-HPLC tR= 17.16 min.  
General synthetic procedure of  carbamate deriva-
tives  (3a-3d). 1 (1 eq) was suspended in dry CH2Cl2 at 0 °C 
and dry pyridine (2 eq) and 1-chloroethyl chloroformate 
(1.2 eq) were added dropwise. The resulting reaction mix-
ture was stirred at 0 °C for 15 min and then warmed to r.t. 
and stirred for a further 3 h. Water was poured into the 
reaction mixture and the crude product was extracted 3 
times with CH2Cl2 and dried over Na2SO4. Crude 1-chloro-
ethyl-5F 203 carbamate was used for the following reaction 
without further purification. 1-chloroethyl-5F 203 carba-
mate (1 eq) was suspended into the corresponding acid (35-
40 eq) and heated at 70 °C. Ag2O (1.2 eq), was added and 
the reaction mixture heated up to 95 °C and stirred for 3 h. 
Ag2O was removed via filtration and the filtrate was col-
lected and concentrated under reduced pressure to afford 
a yellow oil which was further purified by silica gel flash 
chromatography (gradient elution 10-30% EtOAc in petro-
leum ether 40-60 °C). Compounds 3a-3d were obtained 
from trituration in hexane to remove the residual acids. For 
specific experimental procedures, NMR and HPLC anal-
yses and yield of all carbamate analogues (3a-3d), please 
see supplementary information (SI.1-SI.16). 
Cell culture. Human-derived MCF-7 (oestrogen receptor 
positive), HTC-116 colorectal and IGROV-1 ovarian carci-
noma cells, obtained from the American Type Culture Col-
lection (ATCC), were cultured at 37 °C in a humidified at-
mosphere comprising 5% CO2 in a Sanyo LEEC incubator. 
Human-derived cancer cells were grown in RPMI 1640 
(Sigma Aldrich) cell culture medium supplemented with 
10% v/v foetal bovine serum (FBS, Sigma Aldrich) and rou-
tinely subcultured twice weekly to maintain continuous 
logarithmic growth. Normal lung fibroblasts (MRC-5 hu-
man-derived) were grown in Eagle`s minimum essential 
medium (MEM, Sigma Aldrich) supplemented with 10% 
v/v FBS, 100 units penicillin per ml and 0.01 mg per ml 
streptomycin (Sigma Aldrich), 5% v/v L-glutamine (200 
nM, Sigma Aldrich), 5% v/v non-essential amino acids 
(Sigma Aldrich), 5% v/v hepes solution (1 M, Sigma Al-
drich) and 5% v/v sodium bicarbonate solution (7.5%, 
Sigma Aldrich). Experiments were set up when cultures 
reached approximately 70-80% confluence. Experimental 
agents were prepared as 10 mM stock solutions dissolved 
in DMSO and stored at 4 °C, protected from light for a 
maximum period of 4 weeks. 
Growth inhibitory assays (MTT assays). 1 and deriva-
tives 2 and 3a-3d  were prepared as 10 mM top stocks in 
DMSO. Cells were seeded at a density of 3 x 103 per well 
into 96-well microtiter plates and allowed to adhere for 24 
h before test agent was introduced (final concentrations 1 
nM – 10 μM, n = 4). Serial dilutions were prepared in RPMI 
1640 medium immediately prior to addition in each assay. 
At the time of agent addition and following 72 h exposure, 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) was added to each well (final concentration 
400 μg/mL). Incubation at 37 °C for 2.5 h allowed reduction 
of MTT by viable cells (mitochondrial dehydrogenases) to 
insoluble formazan crystals. Well supernatants were re-
moved, and formazan solubilized by addition of DMSO 
(150 μL). Absorbance was read at 550 nm using a Perkin 
Elmer plate reader. Non-linear regression analysis was 
used to calculate compound concentrations required to in-
hibit cell growth by 50% (GI50). 
Western Blot. Whole cell lysates were prepared for exam-
ination of CYP1A1 protein expression from untreated MCF-
7 and HCT-116 cultures and following exposure of cells to 
compounds (1 µM 1, 1 µM 3a, 10 µM 2; 72 h). Following pro-
tein determination (n = 3) and addition of sample buffer, 
samples were heated to 95 °C for 5 min and solubilized pro-
teins (50 µg) were separated by sodium dodecyl sulphate 
(SDS) polyacrylamide gel electrophoresis (PAGE). Proteins 
were electroblotted to polyvinylidene difluoride mem-
branes and probed for CYP1A1 protein with polyclonal an-
tiserum specific for human CYP1A1 (Sigma Aldrich). Sec-
ondary Ab was conjugated to horseradish peroxidase, and 
CYP1A1 was detected by enhanced chemiluminescence. 
Monoclonal anti-GAPDH Ab was used to verify equal pro-
tein loading and transfer. Molecular weight markers and a 
positive control of recombinant CYP1A1 (5 µg; Sigma Al-
drich), included in  blots, confirmed detection of 58 kDa 
CYP1A1 protein. 
Stability test in human plasma and cell growth me-
dium. Human plasma and cell growth medium (RPMI, 
10% FBS) were used to determine enzymatic stability of the 
benzothiazole derivatives 2 and 3a. The medium was pre-
heated to 37 °C prior to the assay for 5 min. The experiment 
was initiated by spiking stock solutions of the benzothia-
zole derivatives 2 and 3a  to give a concentration of 10 μM. 
The reaction mixtures were incubated at 37 °C and shaken 
at 200 rpm on a temperature-controlled orbital shaker 
(Thermo Scientific MaxQ4000, Waltham, MA, USA). Sam-
ples of 100 μL were withdrawn at pre-determined time 
points and the reaction was terminated by addition of ace-
tonitrile. All experiments were conducted in triplicate. 
Benzothiazole derivative  stability test in MCF-7, HCT-
116 cells and their growth medium. Derivative  2 was 
prepared as a 10 mM stock solution in DMSO. MCF-7 and 
 HCT-116 cells were cultured at 37 °C in RPMI 1640 medium 
supplemented with 10% FBS, in 75 cm3 flasks. Flasks were 
prepared in triplicate for each time point: 24 h, 48 h, 72 h. 
Post-seeding (120 h) the medium was aspirated and re-
placed with 15 mL RPMI 1640 medium supplemented with 
2% FBS. The 10 mM stock solution was diluted to 10 μM, 
the cells were treated with 15 μL producing a final concen‐
tration of 1 μM. At the respective time points, 1 mL of cul‐
ture medium was collected for analysis. The remainder was 
aspirated and the cells were washed with 2 x 4 mL PBS prior 
to trypsinization. The cells were collected and centrifuged 
in 50% PBS in medium at 1200 rpm for 5 min. Supernatant 
(1 mL) was collected for analysis and the remainder was as-
pirated leaving a cell pellet. Cell pellets were weighed and 
PBS added 1:1 (w/v). These samples were vortex-mixed and 
100 μL was withdrawn for sample preparation for HPLC 
analysis (see “Analytical Methodology” section for HPLC 
analyses). 
Preparation of Gels. Method A. Samples (5 mg) were 
weighed into 1.5 mL sample vials using an OHAUS semi 
micro-analytical balance. Ultra-purified water (0.5 mL) 
was added and the suspension was sonicated for 1 min. A 
0.5 M solution of NaOH (30 μL) was then added and the 
mixture was sonicated until a clear solution was obtained. 
Glucono-δ-lactone (GdL, 0.7 molar equivalents) was added 
to the solution which was vortexed for 1 min (HatiRota-
mixer). Samples were then allowed to stand for 12 h. Vial 
inversion tests were subsequently carried out as prelimi-
nary screens for gelation. All samples prepared had a final 
concentration of 1 % w/v. 
Preparation of Gels. Method B. The compounds were 
weighed into 1.5 mL sample vials. DMSO was added to cre-
ate a stock solution at 10% w/v. The solution was then soni-
cated in a Sonicor Ultra-sonic bath for 1 min and succes-
sively heated at 60 °C to help full dissolution of the com-
pound. An aliquot (25 μL) of the stock solution was trans‐
ferred to another 1.5 mL vial; the remaining DMSO and 
pre-heated (60 °C) ultra-purified water were added. Sam-
ples were then allowed to cool to room temperature. Vial 
inversion tests were subsequently carried out as prelimi-
nary screens for gelation. All samples prepared had a final 
concentration of 0.5% w/v. 
Rheology. Rheological studies were carried out using an 
Anton Paar MCR302 Modular Compact Rheometer. A four-
bladed vane geometry was used, with a diameter of 8.5 mm 
and length 8.5 mm in a cup with a diameter of 14.5 mm. 
Preparation of hydrogels of 2 was carried out in a 7 mL 
Sterilin plastic sample vial with gelation method A, to 
make a 2 mL gel (1% w/v). After gelation was considered 
complete (12 h), the vial containing the gel was mounted in 
the lower plate of the rheometer (cup) and then the vane 
(attached to the upper part) was lowered into place. This 
arrangement gave a sample depth of approximately 16 mm 
in the 14.5 mm diameter cup which allowed positioning of 
the vane in the centre of the sample. Measurements of the 
storage modulus (Gʹ) and loss modulus (Gʹʹ) as function of 
strain γ, were carried out at a frequency of 10 rad/s. Oscil-
latory frequency sweeps were performed within the linear 
viscoelastic region (LVR) of the gel sample, where Gʹ and 
Gʹʹ moduli are independent of the strain amplitude, under 
a strain of 1%. Preparation of gels of 3 was carried out in a 
7 mL Sterilin plastic sample vial with gelation method B to 
make gels of 2 mL volume (0.5% w/v). Rheological studies 
were performed according to the procedure detailed 
above. For these gels, measurements of Gʹ and Gʹʹ as func-
tion of strain γ, were carried out at a frequency of 10 rad/s. 
Oscillatory frequency sweeps were performed under a 
strain of 0.5%. All measurements were carried out at 37 °C. 
Transmission Electron Microscopy (TEM). TEM anal-
yses were performed using a JEOL JEM-2100 at an acceler-
ated voltage of 200 kV. A 10 μL micropipette was used to 
load a small amount of gel on to a graphene oxide lacey 
carbon hexagonal copper grid (300 mesh, Agar). Excess 
sample was blotted with Whatman 50 filter paper. The grid 
was subjected to high vacuum prior to imaging. Image J 
software was used to analyse TEM images. 
Dissolution studies. Hydrogels of 2 (1% w/v; 0.4 mL) 
were prepared according to method A. The liquid solution 
was pipetted into transwell polyethylene terephthalate 
(PET) membrane inserts (pore size 1.0 μm, Greiner Bio 
One) and allowed to gel for approximately 12 h. The 
transwells were then inserted into 24 well plates contain-
ing 1.2 mL of PBS (pH 7.4) and incubated in a Thermo Sci-
entific MaxQ 4000 Shaker at 37 0C at 15 rpm. At each time 
point a sample (150 μL) was removed from each solution 
and replaced with the same amount of fresh PBS buffer. 
Analyses were performed on a HP1050 RP-HPLC and visu-
alized at 254 nm with a HP1050 variable wavelength ab-
sorbance detector. Spectra were analyzed using Agilent. 
Analytical RP-HPLC was performed using a Phenomenex 
Luna 5 μm C8 (2) 100 Å column (150 mm x 4.60 mm) at a 
flow rate of 1 mL/min. Samples were analyzed using an iso-
cratic method: 70% solvent B in solvent A (solvent A= 0.05 
% TFA in H2O, solvent B= 0.05 % TFA in 9:1 v: v 
CH3CN:H2O). Quantification of known concentrations of 2 
was determined by UV-HPLC measurements and used to 
produce two standard curves, from which unknown con-
centrations of both compounds were determined. 
All data are expressed as mean +/- SD unless stated other-
wise 
3. RESULTS 
The previously reported amino acid derivatives of 1 were 
developed with the aim of creating LMWGs which dis-
played in vitro activity against cancer cell lines. However, 
these previously reported derivatives formed metastable 
gels in mixtures of organic solvents (DMSO) and water.12 
In order to further develop more biocompatible and potent 
gelators of derivatives of 1, two different approaches have 
been considered. The first strategy involved the design and 
synthesis of esterase-sensitive carbamate derivatives of 1 
(3a-3d), in particular acyloxyalkoxycarbonyl derivatives, as 
 previously reported by the pioneering work of Alexander et 
al.25, 26 In addition to this, a second strategy was also con-
sidered, with the aim of comparing the rate of conversion 
of these derivatives into the parent drug and avoiding the 
rapid esterase-mediated hydrolysis. The design choice was 
based on the analysis of the most commonly used linkers 
in the synthesis of stable prodrugs of amines, such as am-
ides, esters, carbamates, phosphates or oximes.23  Several 
examples of N-acylated prodrugs have been reported either 
as successful drugs or in late stage clinical development.24 
Therefore, an approach linking 1 to a succinic acid moiety 
via an amide bond was chosen to increase the derivative 
stability and reduce susceptibility to esterase activity. The 
succinic acid moiety itself was designed to include an alkyl 
chain linked to a terminal free carboxylate. These two func-
tional groups were used as the hydrophobic forces in com-
bination with water solubility, given by a “pH switch”, to 
promote the self-assembly process. Synthetic procedures 
of the carbamate derivatives of 1 are described in the Sup-
porting Information (SI.5-SI.16). 
The growth inhibitory properties of compound 2 and the 
series of carbamate analogues (3a-3d) were then corrobo-
rated by MTT assay following 72 h exposure of cells to the 
test agents. Table 1 shows the differential activity against 
mammary MCF-7 and ovarian IGROV-1 carcinoma cells. 
Activity against MRC-5 normal lung fibroblast cells was 
also evaluated. 
Compounds GI50 mean ± SEM (nM) 
MCF-7 IGROV-1 MRC-5 
1 38.82 ± 4.25 138.24 ± 51.76 > 10000 
2 4754.80 ± 1119.36 5325.85 ± 1312.75 > 10000 
3a 11.63 ± 3.07 43.81 ± 4.75 > 10000 
3b 22.57 ± 7.98 157.35 ± 80.77 > 10000 
3c 39.88 ± 5.32 4261.08 ± 1438.28 > 10000 
3d 81.22 ± 38.18 83.10 ± 11.16 > 10000 
Table 1. Growth inhibitory properties of 1, compound 2 and carbamate 
derivatives 3a-3d against MCF-7, IGROV-1 and MRC-5 cell lines. 
When MCF-7 cancer cells were exposed to derivatives of 1, 
all derivatives retained activity against this cell line. In par-
ticular, the acyloxyalkoxycarbonyl analogues 3a-3d showed 
potent growth inhibitory activity at nanomolar concentra-
tions, with GI50 values similar to those of the parent amine 
1 (GI50 < 100 nM). The succinic acid derivative 2 displayed 
GI50 values in the micromolar range (4.75 μM). MTT assays 
of compound 2 against IGROV-1 revealed micromolar ac-
tivity with a GI50 value of 5.33 μM. Carbamate derivatives 
3a, 3b and 3d displayed GI50 values < 200 nM, similar to 
those of the parent amine 1 (138.24 nM). Compound 3c ex-
hibited higher GI50 values (reduced potency) in the mi-
cromolar range, i.e. 4.26 μM. In both MCF-7 and IGROV-1 
cell lines, dose-dependent inhibition of cancer cell growth 
was observed. In order to demonstrate the selectivity of 
these derivatives against cancer cell lines, MTT assays 
against the MRC-5 normal human embryonic lung fibro-
blast cell line were conducted. MRC-5 fibroblasts were in-
herently resistant to 1;18 similarly, none of the derivatives 2 
and 3a-3d showed any growth inhibitory activity at the 
maximum concentration tested (10 μM), thus revealing 
stark selectivity against the malignant cell lines over the 
non-transformed fibroblasts. Selectivity is also evident be-
tween cancer phenotypes, for example, HCT-116 colorectal 
carcinoma cells are insensitive to 1  (GI50 >50  µM).13 To test 
the hypothesis that modification does not lead to changes 
in the mechanism of action of 1, western blot assays were 
performed to examine CYP1A1 protein expression in lysates 
following treatment of cells (MCF-7 and HCT-116) with 1 
and its derivatives.  Compounds 2 and 3a were included in 
this study. In particular, amongst the acyloxyalkoxycar-
bonyl analogues, 3a was selected because of its remarkable 
in vitro activity displayed against MCF-7 and  IGROV-1 can-
cer cell lines compared to the other derivatives. In accord-
ance with benzothiazole selectivity, neither constitutive 
nor induced CYP1A1 expression could be detected in lysates 
of HCT-116 cells exposed to 1, 2 and 3a. In contrast, in sen-
sitive MCF-7 cells exposed to 1 or 3a (1 µM; 72 h), powerful 
induction of CYP1A1 protein was detected. Correlating with 
its weaker growth inhibitory activity, succinic acid deriva-
tive 2 (10 µM; 72 h) gave more faintly induced CYP1A1 pro-




Figure 2. Selective induction of CYP1A1 protein in MCF-7 (lanes 1-4), 
but not HCT 116 (lanes (6-9) lysates following 72 h exposure of cells to 
vehicle alone (lanes 1 and 6), 1 (lanes 2 and 7), 2 (lanes 3 and 8) or 3a 
(lanes 4 and 9). Lane 5 shows detection of recombinant CYP1A1 (5 µg) 
positive control. Cell lysates containing 50 µg protein were loaded into 
each well. GAPDH protein detection ensured equal electrotransfer of 
proteins onto membranes. 
 
The next step towards development of LMWG-based ben-
zothiazole derivatives was assessment of their in vitro sta-
bility properties in cell growth medium and human 
plasma. Compounds 2 and 3a were chosen as candidates 
for these tests. The succinic acid derivative 2 displayed sta-
bility in both cell growth medium, supplemented with 10% 
FBS, and human plasma, ruling out extracellular cleavage 
of compound 2. On the contrary, when the carbamate de-
rivative 3a was incubated in cell growth medium and hu-
man plasma, complete conversion into 1 occurred, thus 
suggesting its susceptibility to cleavage by extracellular en-
zymes (SI.29). The half-lives of the carbamate derivative 3a 
were 4.18 ± 0.27 h and 1.61 ± 0.11 h in cell growth medium 
 and human plasma, respectively. No additional peaks other 
than the peak for 1 were observed in the HPLC-UV chro-
matograms suggesting direct conversion to 1 (Fig. 3).  Fur-
ther evaluation of the stability of succinic acid derivative 2 
was carried out in MCF-7 sensitive and HCT-116 insensitive 
cells and their culture media.  In insensitive HCT-116 cells 
of 1, as we have confirmed, CYP1A1 is not induced, there-
fore 1 is not bioactivated, and lipophilic 1 is able 
 
Figure 3: Stability of 2 and 3a (1 μM) in (A) cell growth medium and 
(B) human plasma, n = 3. 
 
to diffuse passively across the HCT-116 cell membrane. The 
hypothesis under investigation was that released 1 may be 
detected by HPLC in the insensitive cells. In contrast, sen-
sitive MCF-7 cells rapidly sequester 1 as it binds to cytosolic 
arylhydrocarbon receptor (AhR) triggering AhR pathway 
activation and CYP1A1 induction. 
 
Figure 4: The depletion of 2 (1 µM) from cell growth medium, supple-
mented with 2% FBS, of MCF-7 and HCT-116 cells, n =3. 
 Cells were treated with 1 µM benzothiazole derivative and 
analysed at 24 h, 48 h and 72 h. As shown in Fig. 4, deple-
tion of succinic acid derivative 2 from the cell growth me-
dium was comparable in both MCF-7 and HCT-116 cells. 
However, > 6-fold enhanced intracellular levels of 2 were 
detected in MCF-7 lysates compared to HCT-116 lysates. 1 
was detected in neither sensitive nor insensitive cells (Fig. 
5). 
 
Figure 5: Concentration of 2 in MCF-7 and HCT-116 cells over time, n 
= 3 
 In MCF-7 cells, any released 1 would trigger AhR pathway 
activation and be translocated to nuclei. Low levels of 1 re-
leased from 2 and subsequent bioactivation are consistent 
with faint CYP1A1 induction by succinic acid derivative 2 
and > 100-fold reduced activity compared with free amine 
1 and rapidly hydrolysable carbamate derivative 3a (GI50 
values 4.75 µM compared with <40 nM respectively) in 
MCF-7 cells.  Further investigation revealed emergence of 
a concentration-dependent unknown peak only in cell ly-
sates of insensitive HCT-116 cells; suggesting breakdown or 
metabolism of derivative 2 (SI.28).  
The next step in the development of LMWG derivatives of 
1 was the formulation and characterization of gels of 2 and 
3a-3d. Hydrogels of 2 were prepared using a pH switch 
method, as previously reported in the literature (method 
A).27 Gels of 3a-3c were prepared in binary mixtures of 
DMSO and water at different ratios, with solvent volume 
fractions ɸDMSO up to 0.4.  
Oscillatory amplitude sweeps (SI.24) of hydrogel 2 (1% 
w/v), were performed over a strain from 0.5 to 100%, at a 
constant angular frequency of 10 rad/s and at 37 °C, to 
mimic the physiological conditions at which the gel would 
be used for drug delivery purposes. Results revealed the 
presence of a LVR, with only a slight decrease of the storage 
modulus at high strains. For both amplitude and frequency 
sweeps Gʹ values were higher than Gʹʹ values of at least one 
order of magnitude, as a representative characteristic of 
LMWGs.1 Frequency sweeps were performed over a fre-
quency from 0.1 to 100 rad/s, using a constant strain of 1%. 
A frequency dependence of Gʹ and Gʹʹ was displayed 
throughout the values tested, with Gʹ and Gʺ curves dis-
playing a gradually inclining slope with increasing frequen-
cies, attributable to a low degree cross-linked network (Fig. 
6A). Amongst the acyloxyalkoxycarbonyl derivatives, 3a-3c 
formed visually stable gels in the preliminary vial inversion 
tests, whilst compound 3d did not gelate any of the solvent 
 fractions tested. Analyses of analogue 3a were carried out 
on samples (0.5% w/v) with ɸDMSO of 0.3 and 0.4, solvent 
fractions that gave the most stable gels in the preliminary 
vial inversion tests. Initial analyses showed that for both 
ratios, amplitude (SI.25) and frequency sweeps (Fig. 6B) re-
vealed Gʹ values higher than Gʹʹ values of at least one order 
of magnitude, confirming the LMWG nature of this ana-
logue. Frequency sweeps showed a frequency independ-
ence of Gʹ values up to 25.1 rad/s (ɸDMSO of 0.3) and 39.8 
rad/s (ɸDMSO of 0.4) respectively. Gʹʹ values displayed 
slight frequency dependence in the same range considered. 
With increasing frequencies, breakdown of the gel network 
was observed.28 
 
Figure 6: Frequency sweeps of hydrogel 2 (1% w/v) performed at γ = 1 
% and at 37 °C (A). Frequency sweeps of gel 3a with ɸDMSO of 0.3 and 
0.4, n = 3 at 37 °C, γ = 0.5 % and ω = 0.1-100 rad/s. Standard deviation 
< 18 % (B). All measurements were carried out in triplicate. Error bars 
represent standard deviation. 
 
Correlation between ɸDMSO and gel stiffness was also 
found: a comparison of Gʹ values of 3a in the LVR at 
ɸDMSO of 0.3 and 0.4 showed an increase of this parame-
ter from ~ 400 Pa to ~ 1400 Pa respectively, thus confirming 
the effect of DMSO solvent fractions on gel rigidity as pre-
viously reported for Fmoc-diphenylalanine hydrogels.29  
TEM micrographs of derivatives 2 and 3a-3c confirmed the 
presence of fibers in their gel structures (SI.21 and SI.23). 
However, the two types of derivatives were characterized 
by completely different fiber populations, in terms of mor-
phology and dimensions. Succinic acid derivative 2 formed 
an entangled network of fibers, with a prevalence of thin 
fibers with widths in the region of 35-45 nm and lengths of 
several microns (Fig. 7A). TEM micrographs of gels of 3a at 
ɸDMSO of 0.3 and 0.4 showed the presence of an entangled 
and dense network of fibers, with no differences between 
the two ratios tested, in terms of fiber morphology and di-
mensions. Specifically, both samples displayed a branched 
pattern of fibers, with formation of thick aggregates with 
variable widths between 1100 nm and 400 nm and lengths 
from 8 μm to 32 μm (Fig. 7B).  
1H-NMR spectroscopy analyses of gels of 2 and 3a-3c were 
also carried out to investigate the molecules` functional 
groups involved in the gelation and the dependence of self- 
assembly on temperature and pH (SI.17, SI.18, SI.20, SI.22). 
Time-dependent 1H-NMR spectroscopy studies on hydro-
gel 2 revealed the contribution of the alkyl chain in the self-
assembly. 
Figure 7: TEM micrographs and vial inversion test showing macro-
scopic appearance of sample of hydrogel 2 (1% w/v, scale bar 0.5 μm), 
pH 7.2 (A). TEM micrographs and vial inversion test showing macro-
scopic appearance of sample of gels of 3a (0.5% w/v) at a) ɸDMSO of 
0.3 (scale bar 0.5 μm, B). 
 
Temperature-dependent 1H-NMR spectroscopy analyses 
proved the crucial role of the π-π stacking interactions of 
the benzothiazole core in gel formation; the hydrogen 
bonds of the carbamate group also participated in self-as-
sembly. 
Lastly, dissolution studies from the gel matrix were per-
formed to prove the potential depot formulations of  2 
LMWG for localized drug delivery. The hydrogel of 2 was 
selected as the lead candidate to perform these studies as 
it maintained M potency but didn’t require poorly bio-
compatible DMSO concentrations to create gels as com-
pared to 3a-3c (ɸ DMSO up to 0.4) making LMWG 2 more 
suitable for drug delivery purposes. Dissolution studies 
were carried out under physiological conditions at 37 °C in 
PBS and were performed over 80 h. Results Figure 8: Cumu-
lative release profile of 2 from hydrogel of 2 (1% w/v) in PBS (pH 7.4, 
37 °C). All measurements were carried out in triplicate. Error bars rep-
resent standard deviation. 
 
 showed that 48% of 2 was released from the hydrogel 
within the time considered (Fig. 8). 
4. DISCUSSION 
Two new series of self-assembling gelators based on the 
benzothiazole anticancer agent 1 have been successfully 
developed with the aim of creating a drug delivery platform 
for this experimental antitumour compound. In the pre-
liminary phase of drug design, two different approaches 
have been considered. The first series consisted of esterase-
sensitive carbamate derivatives of 1,  designed accordingly 
to the pioneering work of Alexander et al.25, 26 This led to 
the synthesis of the acyloxyalkoxycarbonyl derivatives 3a-
3d. The succinic acid amide derivative 2, having an alkyl 
chain and a free carboxylic acid terminus, was then devel-
oped with the aim of comparing the rate of conversion  into 
the parent drug and avoiding the rapid esterase-mediated 
hydrolysis. In terms of gelation, drug design of 2 was devel-
oped assuming that the phenyl-benzothiazole moiety of 1 
would have provided the necessary π-π stacking interac‐
tions for initial self-assembly. Introduction of an alkanoic 
acid at the N-position of the native compound via an amide 
bond would have created the hydrophobic forces and the 
hydrogen bond donor and acceptor groups fundamental 
for the self-assembly. Both amide and carbamate series 
demonstrated potent antitumour activity in vitro against 
mammary MCF-7 and ovarian IGROV-1 carcinoma cells. 
They also displayed selectivity against malignant cell lines, 
having negligible impact on MRC-5 embryonic lung fibro-
blast growth. Carbamate deriavtives showed remarkable 
growth inhibitory activity in the nanomolar range com-
pared to the amide derivative 2. This could be attributed to 
the more rapid hydrolysis of 1 from the carbamate deriva-
tive compared to the succinic acid derivative. This theory 
was confimed by the in vitro stability studies in cell growth 
medium and human plasma: succinic acid derivative 2 was 
stable in both media, whereas the carbamate derivative 3a 
displayed complete conversion into the parent amine 1. 
These studies suggested susceptibility of 2 to intracellular 
enzyme and of 3a to extracellular enzyme-hydrolysis. In 
fact, acyloxyalkoxycarbonyl derivates, possessing an enzy-
matically hydrolyzable ester function, readily release the 
parent drugs from the corresponding derivative as a result 
of extracellular esterase activity.26 Stability studies of 2 in 
both MCF-7 sensitive- and HCT-116 insensitive cells and 
their growth medium failed to reveal release of 1. A possible 
explanantion for this in sensitive cells (e.g. MCF-7) could 
be related to the rapid nature in which aminophenylben-
zothiazoles such as 1 are sequestered by cytosolic AhR and 
translocated to the nucleus,30 therefore preventing detec-
tion of 1 by HPLC. An alternative posit could be that 2 itself 
is able to bind cytosolic AhR.  Expression of CYP1A1 was 
weakly induced in MCF-7 cells following their exposure to 
2, and growth was inhibited, inferring some intracellular 
conversion of 2 to parent amine 1, and biotransformation 
to electrophilic species responsible for DNA damage and 
subsequent cell growth inhibition / death in sensitive cells 
which express cytosolic AhR. 17 More powerful induction of 
CYP1A1 was evoked by 1 and 3a – both exhibiting nM po-
tency in MCF-7 and IGROV-1 carcinoma cell lines. Both 
amide and carbamate series were formulated as LMWGs, 
yielding hydrogel 2 and organogels 3a-3c respectively, with 
the aim of creating platforms for the targeted delivery at 
the tumour resection site. It was considered that such a 
formulation, coupled with local delivery would overcome 
general toxicity associated with the previously developed 
lysylamide derivative of 1 (Phortress), which was adminis-
tered systemically (I.V.) and formed persistent adducts in 
DNA rodent lung tissue.31 Rheological characterization of 
hydrogel 2 showed formation of a stable LMWG, with a low 
degree cross-linked network (Gʹ~ 60 Pa). Carbamate deriv-
atives 3a-3c formed more rigid organogels (Gʹ ~ 103 Pa), 
with ɸDMSO up to 0.4. The gels` mechanical characteriza-
tion was also confirmed by their morphological inner 
structure: hydrogel 2 consisted of thin, long fibers within 
the nanometer range, whereas acyloxyalkoxycarbonyl de-
rivatives 3a-3c formed thicker aggregates with lengths in 
the micrometer range. In spite of the higher mechanical 
strength and greater stability of  gels 3a-3c, their poorly-
biocompatible concentrations of DMSO (ɸDMSO up to 
0.4) precluded further development and hydrogel 2 was se-
lected as the lead compound for subsequent dissolution 
studies. Results showed 48% release of 2 from the hydrogel 
matrix over an 80 h period when incubated in PBS, thus 
confirming the drug delivery properties of LMWG 2 for lo-
calized delivery. 
5. CONCLUSION 
In this work we have reported design and development of 
novel self-assembling gelators based on 1. Two different 
types of derivatives were synthesized, formed by an amide 
(2) and a carbamate (3a-3d) linker, respectively; they main-
tained selective and potent in vitro antitumour activity 
against mammary and ovarian carcinoma cells. The ability 
to form stable gelators under relatively high strains was 
supported by rheological tests, and their morphology was 
characterized by a crossed-linked nanostructure. Finally, 
in vitro dissolution studies proved the ability of hydrogel 2 
to act as a delivery platform for localized delivery. 
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